6533b825fe1ef96bd12832c8
RESEARCH PRODUCT
Randomised placebo-controlled trial of moclobemide, cognitive–behavioural therapy and their combination in panic disorder with agoraphobia
Bernd LoerchMechthild Graf-morgensternChristoph HainJuergen SandmannS. SchlegelOtto BenkertMartin Hautzingersubject
AdultMalemedicine.medical_specialtyAdolescentPanic Disorder with AgoraphobiaMoclobemidemedicine.medical_treatmentPlacebo-controlled studyPlacebobehavioral disciplines and activities03 medical and health sciences0302 clinical medicinemental disordersMoclobemidemedicineHumans030212 general & internal medicinePsychiatryAgoraphobiaAgedAnalysis of VarianceCognitive Behavioral TherapyPanicFearMiddle Agedmedicine.diseaseCombined Modality TherapyAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTreatment OutcomeBenzamidesCognitive therapyPhysical therapyPanic DisorderPatient ComplianceFemalemedicine.symptomPsychologyAnxiety disorderFollow-Up Studiesmedicine.drugAgoraphobiadescription
BackgroundIn the treatment of panic disorder with agoraphobia, the efficacy of pharmacological, psychological and combined treatments has been established. Unanswered questions concern the relative efficacy of such treatments.AimsTo demonstrate that moclobemide and cognitive–behavioural therapy (CBT) are effective singly and more effective in combination.MethodFifty-five patients were randomly assigned to an eight-week treatment of: moclobemide plus CBT; moclobemide plus clinical management (‘psychological placebo’); placebo plus CBT; or placebo plus clinical management.ResultsComparisons between treatments revealed strong effects for CBT. Moclobemide with clinical management was not superior to placebo. The combination of moclobemide with CBT did not yield significantly better short-term results than CBT with placebo. The CBT results remained stable during a six-month follow-up, although a substantial proportion of patients treated with placebo plus CBT needed additional treatment.ConclusionsCBT was highly effective in the treatment of panic disorder with agoraphobia and reduced agoraphobia to levels that were comparable to those of non-clinical controls.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1999-03-01 | British Journal of Psychiatry |